New Study Demonstrates Consistent Positive Long-Term Adherence and Efficacy of Nerivio® for Treatment of Migraine

Advances in Therapy Publishes Study Finding 12-Month Consistency in Utilization and Efficacy of Non-Drug, Non-Disruptive Wearable to Mitigate Migraine Burden

NETANYA, Israel and BRIDGEWATER, N.J., Oct. 25, 2023 /PRNewswire/ -- Theranica, a neuromodulation therapeutics company, announced the publication of a comprehensive clinical study in Advances in Therapy examining the long-term utilization, clinical efficacy, and safety of Nerivio

®, a Remote Electrical Neuromodulation (REN) device for the treatment of migraine.

Continue Reading

Preview

来源: PRNewswire

Nerivio is indicated for dual-use in people 12 years and older

The study included 409 participants across the entire USA  who used Nerivio device for acute treatment of migraine for 12 consecutive months, reporting their data prospectively. The results showed consistent and persistent efficacy in pain relief, pain freedom, functional disability relief, and functional disability freedom, as well as consistent adherence.

Dr. Andrea Synowiec, a neurologist and headache specialist who serves as System Vice Chair of the Department of Neurology at Allegheny Health Network in Pennsylvania is the lead author of the study. She emphasized the significance of these findings stating, "When assessing the clinical benefits of therapies for chronic neurological disorders such as migraine, it's important to evaluate patient adherence and clinical efficacy over a long period of time, in order to eliminate possible tachyphylaxis or waning over time. This large sample size study gives physicians and patients alike the evidence-based confidence that the impact of Remote Electrical Neuromodulation (REN) with Nerivio is sustainable over a long time. Adherence to treatment is crucial to obtaining maximal efficacy, and the persistent 12-month adherence demonstrated in this study is very encouraging".

During the study period, users performed a total of 39,531 treatments, with a monthly average of 8.05 treatments per patient, and a standard deviation (SD) of 1.15, meaning that the month-to-month number of treatments per patients did not differ significantly along the 12 consecutive months. The non-disruptive nature of using Nerivio is designed to promote high adherence: the device can be worn under a shirt or jacket sleeve, and is self-controlled through a user-friendly smartphone app, making it ideal for discreet usage even in places that are not private, like a school class, a work office, or on a bus or a train.

Notably, the rate of device-related adverse events was extremely low - less than 2%.

As for clinical efficacy, 74.1% of the participants reported consistent 2-hour pain relief, and 26% reported consistent pain freedom.

"With migraine being almost a life-long disease, patients need therapies they can rely on to help them maintain their quality of life and reduce the burden of the disease," said Alon Ironi, CEO and co-founder of Theranica. "Whether you are a high school student, a police officer, or a musician, if you live with migraine, you want a trustworthy treatment that combines persistent high efficacy, minimal side effects and ease of use. We designed Nerivio with exactly these requirements in mind."

"Theranica is committed to addressing migraine, with special emphasis on patient groups who typically have fewer therapy options, such as adolescents, veterans and active-duty service personnel, and pregnant women", added Ironi.

About Nerivio

Controlled by a smartphone app and self-administered, Nerivio wraps around the upper arm and uses sub-painful Remote Electrical Neuromodulation (REN) to activate nociceptive nerve fibers in the arm to send signals which trigger a descending pain management mechanism in the brain called conditioned pain modulation (CPM), which turns off migraine pain and associated symptoms without medication. In simpler terms, the upper arm is stimulated to unleash a natural process in the brain to abort or relieve migraine headaches and other associated symptoms. Each treatment lasts 45 minutes and is applied every other day for prevention or at the start of a migraine attack for acute treatment.

About Theranica

Theranica is a neuromodulation therapeutics company dedicated to creating effective, safe, affordable, low-side-effect therapies for idiopathic pain conditions. The company's award-winning flagship wearable, Nerivio®, is an FDA-cleared and CE-marked prescription device for complete care of migraine - acute and/or preventive treatment of chronic or episodic migraine with or without aura in people 12 years or older. Nerivio has been used in more than 600,000 migraine treatments in the US, including by adolescents and veterans living with migraine. Theranica is expanding its proprietary technology to develop solutions for additional idiopathic pain conditions. Learn more by visiting our websites, theranica.com and nerivio.com, and following us on LinkedIn, Twitter, Instagram and Facebook.

Theranica Contact

Ronen Jashek

[email protected]

+972-72-390-9750

Media Contact

V.A. Lopes

Grey Matter Marketing

[email protected]

SOURCE Theranica

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。